Skip to main content

Table 7 Results: ICER (3% discounted costs and outcomes)

From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Parameter

ICER

LY

 

Total (mean)

15,568.65

- BPD

4,332.29

- < 33 weeks

17,885.86

- 33–35 weeks

28,417.08

QALY

 

Total (mean)

8,676.74

- BPD

2,731.81

- < 33 weeks

9,380.00

- 33–35 weeks

14,937.32

Back to article page

Italian Journal of Pediatrics

ISSN: 1824-7288

Contact us